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Abstract
Background: Circulating levels of novel long-chain hydroxy fatty acids (called GTAs) were recently discovered in
the serum of healthy subjects which were shown to be reduced in subjects with colorectal cancer (CRC),
independent of tumor burden or disease stage. The levels of GTAs were subsequently observed to exhibit an
inverse association with age in the general population. The current work investigates the biological activity of
these fatty acids by evaluating the effects of enriched human serum extracts on cell growth and inflammation.
Methods: GTAs were extracted from commercially available bulk human serum and then chromatographically
separated into enriched (GTA-positive) and depleted (GTA-negative) fractions. SW620, MCF7 and LPS stimulated
RAW264.7 cells were treated with various concentrations of the GTA-positive and GTA-negative extracts, and the
effects on cell growth and inflammation determined.
Results: Enriched fractions resulted in poly-ADP ribose polymerase (PARP) cleavage, suppression of NFB, induction
of IBa, and reduction in NOS2 mRNA transcript levels. In RAW264.7 mouse macrophage cells, incubation with
enriched fractions prior to treatment with LPS blocked the induction of several pro-inflammatory markers including
nitric oxide, TNFa, IL-1b, NOS2 and COX2.
Conclusions: Our results show that human serum extracts enriched with endogenous long-chain hydroxy fatty
acids possess anti-inflammatory and anti-proliferative activity. These findings support a hypothesis that the
reduction of these metabolites with age may result in a compromised ability to defend against uncontrolled cell
growth and inflammation, and could therefore represent a significant risk for the development of CRC.
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Background
Fatty acid metabolism is intricately linked to the regula-
tion of inflammatory processes, which underlie numer-
ous diseases including cancer. For example, arachidonic,
decosahexanoic and eicosapentanoic acids (AA, DHA
and EPA) can be metabolized into both pro-inflamma-
tory prostaglandins and leukotrienes, as well as into
inflammation-resolving lipoxins, protectins and resolvins
[1-3]. The failure to resolve acute inflammation through
a lack of conversion to these latter products can result
in a chronic inflammatory state, which over time can
drive the development of inflammation-associated con-
ditions including cancer, neurodegeneration, and others
[4-10]. Functionally, many of these lipids have been
shown to mediate their inflammation-associated effects
through pathways involving the transcription factor
NFBa n ds u b s e q u e n td o w n s t ream pro-inflammatory
molecules such as TNFa,I L - 1 b, COX2, and NOS2, for
example [11-16].
Recently we reported on a novel class of hydroxylated
long-chain fatty acids (called GTAs for gastrointestinal
tract acids) present in the serum of healthy subjects and
significantly reduced from the serum of colorectal cancer
(CRC) patients [17,18]. Structurally, the molecules resem-
ble very long chain (28 carbon) mimetics of the resolvins
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least two hydroxyl groups. The levels of GTAs do not
change following treatment and show no correlation with
tumor stage, suggesting that the reduction is not caused
by the presence of the disease [17,18]. An inverse associa-
tion between GTAs and age in the average-risk population
further suggests that the reduction exists prior to cancer
development, and may therefore represent a causal factor
for the establishment and/or progression of the disease
[18]. However, little is currently known about the bio-
chemical role these molecules play in the disease process.
The work reported herein, therefore, was carried out to
investigate the effects of GTAs in vitro through the treat-
ment of various cell lines with semi-purified GTA-
enriched human serum extracts.
Methods
Cell lines and tissue culture
SW620, MCF-7 and RAW264.7 were purchased from
ATCC and cultured in high glucose DMEM, 10% FBS at
37°C, 5% CO2. Cells were seeded at 1 × 10
6/well in 6-
well plates 24 hours prior to treatment with varying
concentrations of GTA+ve extract, GTA-ve extract or
vehicle (DMSO). RAW264.7 cells were pretreated with
the extracts for 4 hours followed by the addition of LPS
at 1 ug/ml (cat. No. L4391, Sigma) for 20 hours. Cells
were harvested using a 2:1 ratio of Versene and TryPLe
express (Gibco). The cell pellet was washed twice with
phosphate buffered saline (PBS) and the stored at -80°C
until extracted. Cell photographs were taken at 200×
magnification on a phase-contrast EVOS digital micro-
scope. All experiments were performed at least three
times in duplicate or triplicate wells.
Serum extraction, chromatography and mass
spectrometry
Commercially available lyopholized human serum (Ran-
dox Laboratories, Canada) was resolubilized in double
de-ionized water. The serum was extracted with 1:5
ratio of 1% ammonium hydroxide:ethyl acetate (Com-
mercial grade, VWR) as previously described [17]. Ethyl
acetate extracts were evaporated to dryness under
reduced pressure (37°C/100 rpm) and re-suspended in
methanol. Reverse phase silica (15 - 20 mg; WP C18
silica, 45 μm, 275 Å) was added into the serum metha-
nol extract and evaporated to complete dryness under
reduced pressure (45°C/150 rpm), which was then sub-
jected to reverse phase flash column chromatography
(FCC) with a step gradient elution; acetonitrile - water
25:75 to 100% acetonitrile. Eluent was fractionated into
12 aliquots (F1 - F12), which were each analysed for
GTA content using HPLC-coupled tandem mass spec-
trometry on an ABI QSTAR XL mass spectrometer as
previously described [17].
Proliferation assays
Cell proliferation was determined using the MTT assay
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide). Cell suspensions were prepared at a concen-
tration of approximately 10
5 cells per ml as determined
by standard hemocytometry, and cultured in 6-well
multi-well plates. Prior to MTT analysis, cells were sub-
cultured in phenol red-free DMEM medium to avoid
interference with the colorimetric analysis of the purple
formazan MTT product. Following treatment with
serum extracts, cells were treated with MTT followed
by washing with PBS, DMSO solubilization of the for-
mazan product, and subjected to spectrophotometric
analysis at 570 nm.
Protein analysis
Cell pellets were resuspended in ice-cold lysis buffer (20
mM Tris (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.1
mM EGTA, 0.1% NP-40 plus 1X mammalian cell anti-
protease cocktail (Sigma)). The cells were lysed using mul-
tiple freeze-thaw cycles followed by pulse sonication on
ice and centrifugation at 3000 rpm for 5 minutes at 4°C
to remove cell debris. Western blot analysis of these pro-
tein lysates was performed as previously described [19].
Briefly, equivalent amounts of protein were assessed by
Bradford protein assay using BioRad Protein Reagent and
resolved by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Following electrophor-
esis the proteins were trans-blotted onto nitrocellulose
membranes (Pall-VWR). The membranes were blocked
overnight at 4°C on a gyratory plate with 5% molecular
grade skim milk powder (BioRad Laboratories) in phos-
phate-buffered saline (PBS) containing 0.1% Tween-20
(PBST). Primary and secondary antibody incubations and
subsequent washes were carried out in the same buffer.
Primary antibodies were obtained from Santa Cruz Bio-
technology. The primary antibody for GAPDH was pur-
chased from Sigma. Secondary HRP antibodies were
purchased from BioRad. Blots were immunoprobed over-
night with primary antibodies at a 1:1000 dilution. Sec-
ondary HRP antibody was applied at room temperature
on a gyratory plate at a concentration of 1:10,000 for 30
min. Following multiple washes, an enhanced chemilumi-
nescence detection system (Dupont-NEN) was used to
detect the target antigen/antibody complexes. Blots were
then stripped at 50°C for 30 minutes in a Tris-buffered
20% SDS/1% 2-mercaptoethanol stripping solution,
washed and re-probed with GAPDH antibody (Sigma) to
verify protein loading equivalency. For ELISA analysis,
raw cells were treated as described above and conditioned
medium or cell lysates were used to determine concentra-
tions of TNFa (Cat. No. KMC3011, Invitrogen), and IL-
1b (Cat. No. MLB00B, Quantikine), according to the man-
ufacturer’s instructions.
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Nitrite concentration in conditioned media was mea-
sured by Griess Reagent (Cat. No. G2930, Promega)
according to the manufacturer’s instructions.
Quantitative Real-Time PCR
Total RNA was isolated from cell pellets using Trizol
(Cat. No.15596-018, Invitrogen) as per manufacturer’s
instruction. RNA was resuspended in 50 μL of DEPC
treated water and stored at -80°C. RNA concentration
and purity was determined by spectrophotometry at 260
and 280 nm. Reverse transcription was performed using
qScript cDNA super mix (Cat No. 95048-100, Quanta
Biosciences). PCR was conducted by using Fast SYBR
Green Master Mix (Cat No. 4385612, AB Applied Bio-
systems) on an Applied Biosystems Step One Plus Real-
time PCR system. The relative number of each tran-
script copy was normalized by house-keeping gene Beta
Actin. Real-time PCR primers used were as follows:
NOS2 forward, CACCTTGGAGTTCACCCAGT; NOS2
reverse, ACCACTCGTACTTGGGATGC; COX2 for-
ward, CCCCCACAGTCAAAGACACT; COX2 reverse,
CTCATCACCCCACTCAGGAT; TNFa forward, AG
AAGTTCCCAAATGGCCTC; TNFa reverse, GTC
TTTGAGATCCATGCCGT; IL-1b forward, TGTGA
AATGCCACCTTTTGA; IL-1b reverse, TGAGTG
ATACTGCCTGCCTG.
Clinical Samples
Serum from a previously reported CRC patient and con-
trol population originating from Chiba University was
equally pooled [17]. Ethyl-acetate extracts of the pooled
control and CRC serum were subject to HPLC-coupled
tandem mass spectrometry to determine relative GTA
levels as previously described [17].
Statistical Methods
Where data is averaged, error bars represent 1 standard
deviation (S.D.) of the mean. Significance was deter-
mined if p < 0.05 using unpaired Student’sTt e s t
(Microsoft Excel).
Results
Treatment of cells with un-enriched human serum
extracts
We first determined whether crude serum ethyl acetate
extract, prior to chromatographic enrichment of GTAs,
would have any effect on cellular growth by treating
cells with commercially available bulk human serum
extracts (see methods). The total ion chromatogram
(TIC) of the organic fraction following HPLC-coupled
time-of-flight (TOF) mass spectrometry is shown in Fig-
ure 1A. The extracted mass spectra of the complete TIC
is shown in Figure 1B, which was dominated by various
free fatty acids but contained detectable levels of GTAs
including those with masses of 446 (C28H46O4), 448
(C28H48O4) and 450 (C28H50O4) Da (Figures 1B and
1C). By calculating the peak areas of the three chroma-
tograms, we estimated that these three GTAs repre-
sented no more than 0.15% of the total ion current in
the sample. Incubation of SW620 cells with up to 80
ug/ml of the extract for 48 hours showed no effect on
cell proliferation (Figure 1D) or any effects on cell mor-
phology as assessed by light microscopy (not shown).
Organic serum extract was next subjected to flash col-
umn chromatography as described in the methods,
resulting in 12 fractions which were subsequently ana-
lyzed by HPLC-MS to determine GTA content.
Although other components were present in all the frac-
tions, only fraction 9 out of the 12 was enriched for the
C 2 8G T A s( r e f e r r e dt oa st h eG T A + v ef r a c t i o n ) .A
GTA negative control fraction (fraction 8, lacking any
detectable GTAs) was also selected for the studies
described below. Representative total ion chromato-
grams, extracted mass spectra and selected ion chroma-
tograms of the three C28 GTAs for the GTA-ve and
GTA+ve fractions are shown in Figures 2A and 2B,
respectively. By comparing the sums of the selected ion
chromatograms of the three GTAs to the total ion cur-
rents, we estimated that the GTA+ve fraction contained
approximately 21% C28 GTAsw h i l et h eG T A - v ef r a c -
tion had no detectable levels (bottom panel of Figures
2A and 2B). The non-GTA background components for
both fractions were similar, and the most abundant
non-GTA components in the GTA+ve fraction were
also the most abundant components in the GTA-ve
fraction. Therefore, the two fractions were composition-
ally similar other than the 21% GTA content of the
GTA+ve fraction, which represented an approximately
143-fold enrichment of the three C28 GTA metabolites
over the crude organic serum extract (as shown in Fig-
ure 1A). These fractionations were repeated several
times with consistent results. We therefore concluded
that the fractions were sufficiently matched for investi-
gating biological activity as described below. For com-
parison, the relative levels of the three C28 GTAs from
40 pooled CRC patients’ serum and serum from 40
matched control subjects is shown in Figure 2C.
GTA+ve human serum extracts inhibit cell proliferation
and induce PARP fragmentation
We determined whether the enriched GTA+ve fraction
had any effects on cell viability compared to the GTA-
ve fraction by treating SW620 cells for 24 hrs with three
concentrations of each fraction and measuring the effect
on cell proliferation by MTT assay. The GTA+ve frac-
tion showed a 40% reduction in cell viability at a dose
of 80 ug/ml (Figure 3A) while GTA-ve treatment had
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showed the same 40% reduction as early as 12 hrs,
which dropped further to 70% by 48 hrs (Figure 3B). No
effect on cell proliferation was observed with the GTA-
ve fraction or vehicle (DMSO). Evidence of apoptotic
activity was determined by the detection of poly(ADP-
ribose) polymerase (PARP) cleavage products through
Western blot (Figure 3C). A number of PARP cleavage
products including the hallmark 89 and 24 kDa frag-
ments, as well as others (Figu r e3 C ) ,w e r ei n d u c e df o l -
lowing 48 hrs treatment with GTA+ve fraction, but not
with GTA-ve treatment, suggesting a possible pro-apop-
totic function of GTAs.
We repeated the studies in MCF7 cells, which upon
treatment with GTA+ve fraction showed gross cellular
changes visible through phase-contrast microscopy
including the appearance of apoptosomes and enlarged
nuclei that were not observed with vehicle or GTA-ve
treatments (Figures 4A, B and 4C). GTA+ve treatment
in MCF-7 cells also resulted in the exclusive induction
of the 24 kDa PARP cleavage product relative to vehi-
cle or GTA-ve treatment (Figure 4D), further suggest-
ing a pro-apoptotic activity of GTA-containing
extracts.
GTA+ve extracts inhibit pro-inflammatory markers
The structural resemblance of GTAs to the inflamma-
tion-resolving protectins and resolvins prompted us to
investigate the effect of GTA+ve extract on pro-inflam-
matory markers. Treatment of SW620 cells for 24 hours
resulted in a profound inhibition of NFB protein level
with as little as 20 ug/ml GTA+ve extract, accompanied
by an equally profound induction of IBa,n e i t h e ro f
which was observed with GTA-ve extract (Figure 5).
Protein levels of nitric oxide synthase (NOS2) were also
inhibited in cells treated with the GTA+ve fraction (par-
ticularly 20 and 40 ug/ml), but not in cells treated with
the GTA-ve fraction (Figure 5).
Figure 1 Total ion chromatogram of crude serum organic extract. (A) Total ion current of bulk serum following liquid/liquid extraction and
HPLC-coupled mass spectrometry as explained in the methods. (B) Extracted mass spectra of all masses from (A). (C) Extracted ion
chromatograms of GTAs 446, 448 and 450 from the total ion current shown in A. (D) Cell proliferation, as assayed by MTT, for SW620 cells
treated with up to 80 ug/ml of the crude serum extract.
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1) was subject to flash column chromatography as described in the methods resulting in two adjacent eluates, one positive and one negative
for the presence of GTAs. The total ion chromatogram (top), extracted mass spectra (middle), and extracted ion chromatograms for three GTAs
(GTA446, 448 and 450; bottom) of the GTA-ve fraction. (B) Same as (A) for the GTA+ve fraction. (C) For comparison, the extracted ion
chromatograms of GTA446, 448 and 450 from the extracts of serum pooled from 20 CRC patients and 20 controls is shown.
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inflammation, we employed the RAW264.7 mouse
macrophage line in which a pro-inflammatory state
can be induced by treatment with lipopolysaccharide
(LPS). RAW264.7 cells were treated for 4 hours with
GTA+ve and GTA-ve fractions prior to the addition of
LPS, and the effects on various proinflammatory mar-
kers evaluated. We observed no affect on RAW264.7
cell growth or proliferation rates during the 20 hours
post-GTA treatment. RAW264.7 cells treated with
GTA+ve fractions prior to LPS stimulation showed a
significant dose-dependent reduction (p < 0.05) in the
generation of nitric oxide as assessed through the pro-
duction of nitrite using the Griess reagent system (Fig-
ure 6A), which was mirrored by low levels of NOS2
mRNA transcripts (Figure 6B) and protein levels (Fig-
ure 6C). For comparison (and as controls), cells were
also treated with various combinations of free fatty
acids including EPA, DHA and equimolar mixtures of
18:1, 18:2 and 18:3 (FA mix), of which only 100 uM
DHA showed any protective effect on NOS2 protein
induction (Figure 6C).
Similar effects were observed with TNFa upon treat-
ment with GTA+ve extract, which showed significantly
reduced mRNA transcript levels (p < 0.05, Figure 7A) as
well as protein levels in cell lysates and conditioned
media (Figures 7B and 7C, respectively). Consistent with
the above findings, transcript levels of COX2 and IL-1b
(Figures 8A and 8B), as well as IL-1b protein levels (Fig-
ure 8C), were also significantly reduced (p < 0.05) with
GTA+ve treatment. The results indicate that human
blood extracts containing GTAs have anti-proliferative
and anti-inflammatory properties that GTA-ve extracts
lack.
Figure 3 Proliferation of SW620 cells treated with GTA+ve and GTA-ve extracts. (A) SW620 cells were incubated with increasing
concentrations of GTA+ve and GTA-ve extracts for 24 hours and proliferation assayed by MTT. (B) The 80 ug/ml concentration of GTA+ve and
GTA-ve extracts was then used to treat cells for up to 48 hours and the effect on cell proliferation assayed by MTT. Data are expressed as
percent of vehicle or 0 hrs ± 1S.D. (C) Representative Western blot analysis of caspase-mediated PARP cleavage fragments resulting from
treatment with GTA+ve and -ve extracts. Experiments were repeated at least three times.
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The regulation of inflammation and the ability to con-
trol cell growth are two processes intricately linked with
cancer. When acute inflammatory processes are not
resolved by the appropriate enzymatic conversion of
fatty acid mediators into specific oxygenated products
[1,20,21], a state of chronic inflammation can ensue,
which can further lead to sporadic DNA mutations, the
activation of pro-oncogenic pathways and ultimately
cancer (for example see [22]). When such detriments
occur, they normally trigger a cascade of intracellular
events leading to the induction of apoptotic-mediated
cell death. Thus it is the fine control between inflamma-
tory and apoptotic processes, likely early in life, which
m i g h tb eak e yd e t e r m i n a n to fo n e ’sr i s ko fs u b s e q u e n t
cancer development.
Based on the tumor-independent reduction of GTAs
previously reported in CRC patient serum [17], their
age-related reduction in the general population [18], and
their structural resemblance to the inflammation-resol-
ving protectins and resolvins, we hypothesized that
GTAs might represent a novel endogenous cancer-pro-
tective metabolic system. Although we focused
Figure 4 Treatment of MCF7 cells with GTA+ve and GTA-ve extracts. MCF7 cells were incubated with vehicle (A), 80 ug/ml GTA+ve extract
(B), and 80 ug/ml GTA-ve extract (C) and cells photographed using phase-contrast light microscopy (200×). (D) Western analysis of PARP
cleavage products; ns, non-specific.
Figure 5 Western analysis of NFB, IBa and NOS2 in SW620
cells treated with three concentrations of GTA+ve and GTA-ve
extracts and doxorubicin (DOX). Representative Western blots
showing protein levels of NFB, IBa and NOS2 in SW620 cells
treated with GTA+ve and GTA-ve extracts (see methods).
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family comprises a large number of structurally related
novel hydroxylated polyunsaturated ultra long-chain
fatty acids ranging in size between 446 and 596 Da and
containing up to 36 carbons [17].
In studies completed to date, GTAs appear to repre-
sent a human-specific metabolic system as they have
only been detected in human serum (or plasma) and not
in the serum or plasma of other mammals including
mice, rats, cows, dogs, and rabbits. Likewise, GTAs are
Figure 6 Determination of nitric oxide status in RAW264.7 cells
treated with GTA+ve and GTA-ve extracts. RAW264.7 cells were
pre-treated for 4 hours with GTA+ve or GTA-ve extracts followed by
the addition of LPS (1 ug/ml) for 20 hours. (A) Nitric oxide levels in
cells were determined using Griess reagent, (B) NOS2 mRNA
transcript levels were determined by real-time rtPCR, and (C) NOS
protein (treatment with 80 ug/ml) assessed by Western blot (NS,
non-specific). Asterisks indicate p < 0.05 relative to LPS treatment
alone, and FA mix in (C) represents a 100 uM equal mixture of 18:1,
18:2 and 18:3 fatty acids. Data are expressed as the average of three
duplicate experiments ± 1S.D.
Figure 7 TNFa response in RAW264.7 cells treated with GTA
+ve and GTA-ve extracts. RAW264.7 cells were pre-treated for 4
hours with GTA+ve or GTA-ve extracts followed by the addition of
LPS (1 ug/ml) for 20 hours. (A) TNFa mRNA transcripts as
determined by real-time rtPCR, (B) TNFa relative protein levels in
cell lysates following 80 ug/ml treatment, and (C) TNFa protein
levels in conditioned media as determined by ELISA. Asterisks
indicate p < 0.05 relative to LPS treatment alone. Data are
expressed as the average of three duplicate experiments ± 1S.D.
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as grains and seed oils, as well as human tissues includ-
ing colonic tumors and normal colon epithelium
(unpublished observations). This human exclusivity has
lead us to speculate that the gut microbiota, in
combination with currently unknown dietary precursors,
may be involved in their catabolism. The results shown
here represent the first report of GTA biological activity,
which revealed that cells treated with GTA+ve extracts
had reduced proliferative capacity coinciding with PARP
fragmentation, significantly down-regulated NFB
expression, increased IBa levels, and numerous down-
regulated inflammatory markers including nitric oxide,
NOS2, IL-1b,T N F a and COX2. Given the critical role
of NFB in regulating both apoptosis and inflammation
and its association with aging, our data suggests that the
protective effects of GTAs are mediated, at least in part,
through NFB signalling. A reduction of GTAs over
time could therefore be involved in compromising one’s
ability to protect against chronic inflammation and pos-
sibly cancer.
GTAs, fatty acids, and proliferation
Our observation that GTA+ve extracts dose-depen-
dently reduce cell proliferation, accompanied by the
appearance of multiple PARP cleavage products with
different molecular weights in SW620 cells but only
the 24 kDa fragment in MCF-7 cells, suggests a com-
plex cell-specific interplay between different proteases.
Although it has been reported that caspase-3 activation
can result in the 89 and 24 kDa fragments and that
cathepsin-b and granzyme-b can produce fragments of
50 and 64 kDa, respectively [23], further work will be
required to investigate GTA-specific protease activa-
tion. Our evidence of apoptosis upon treatment with
GTAs is consistent with numerous other reports show-
ing pro-apoptotic effects mediated through polyunsatu-
rated long chain fatty acids (PUFAs). For example,
docosahexanaeoic acid (DHA) has been shown to pro-
mote apoptosis through numerous pathways including
cytochrome-c mediated caspase activation [24,25], inhi-
bition of the regulatory subunit of PI3-kinase, and
reduction of PTEN phosphorylation [24,26]. Others
have shown that DHA and the PUFA punicic acid ulti-
mately exert their intrinsic effects through dissipation
of the mitochondrial membrane potential [27,28], and
that DHA and butyrate can promote apoptosis by
altering mitochondrial Ca
2+ levels [29]. Treatment of
various cell lines, for example LAPC-4 prostate cancer-
d e r i v e dc e l l s ,w i t hP U F A s ,h a sb e e ns h o w nt or e d u c e
proliferation and induce apoptosis [30]. There are also
studies demonstrating the inhibitory effects of omega-3
PUFAs on growth and angiogenesis of chemically
induced as well as transplanted tumor model systems
[31-33]. The observation of reduced cell growth in the
presence of GTA+ve extract is therefore consistent
with a large body of literature showing similar effects
with exposure to long-chain PUFAs (see [34] for
review).
Figure 8 COX2 and IL-1b response in RAW264.7 cells treated
with GTA+ve and GTA-ve extracts. RAW264.7 cells were pre-
treated for 4 hours with GTA+ve or GTA-ve extracts followed by the
addition of LPS (1 ug/ml) for 20 hours. (A) COX2 and (B) IL-1b
mRNA levels were determined by real-time rtPCR. (C) IL-1b levels
following 80 ug/ml treatment in cell lysates as determined by ELISA.
Asterisks indicate p < 0.05 relative to LPS treatment alone. Data are
expressed as the average of three duplicate experiments ± 1S.D.
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extract also protected against the LPS-mediated induc-
tion of several pro-inflammatory proteins including
TNFa,I L - 1 b, NOS2 and COX2, and inhibited the pro-
duction of nitric oxide. Central to these two effects
(reduced proliferation and inflammation) was the con-
comitant inhibition of NFB upon GTA+ve treatment
in SW620 colonic epithelial cells, which correlated pre-
cisely with increased levels of the inhibitory protein
IBa, likely due to stabilization stemming from compro-
mised ubiquitin-dependent proteosomal targeting [35].
The inhibition of NFB is relevant to both apoptotic
processes and inflammation, as discussed further below.
NFB and cell proliferation
NFB, a transcription factor represented by a series of
subunits harbouring discrete DNA binding and transac-
tivational functionality, is implicated in both intrinsic
and extrinsic apoptotic pathways (see [36] for review)
and has been shown to prevent apoptosis as well as pro-
mote transformation in epithelial-derived cancers [37].
Mechanistically, in the absence of NFB signalling, inhi-
bitor-of-apoptosis proteins (IAPs) fail to suppress
assembly of the death-inducing complex II, which allows
for the TRADD-mediated activation of caspase-8 and
subsequent apoptosis [36,38]. Furthermore, IAPs can
directly promote the ubiquitin-mediated degradation of
the NFB-inducing serine/threonine kinase (NIK), ulti-
mately resulting in NFB activation [39]. Although a
detailed discussion on this topic is out of scope, it is
well established that activated NFB is associated with
an anti-apoptotic pro-survival advantage which is rele-
vant given our data showing that GTA+ve extracts
reduced NFB expression. These observations are con-
sistent with the reported biological activity of the resol-
vins and protectins, which have been shown to exert
both pro-apoptotic effects [40] and the resolution of
inflammation by attenuating cytokine levels in an
NFB-dependent manner [41]. One limitation of our
study was that we were unable to determine NFB
levels in RAW264.7 cells, which will require further
investigation upon the generation of sufficient quantities
of either enriched extract, or more preferably, purified
synthetic GTAs. However, the dramatic reduction of
NFB upon GTA treatment in colon tumor cells is
highly relevant given the reduced levels of circulating
GTAs in CRC patients [17,18] and the well-established
inflammatory component of this disease [42].
NFB and inflammation
Besides its anti-apoptotic role, NFBr e p r e s e n t sak e y
link between inflammation and cancer (see [43] for
review), and in particular, is considered a master regula-
tor of intestinal immunological function and activator of
factors involved in driving intestinal inflammation
[44-46]. NFB activation has been observed in numer-
ous GI-related conditions including inflammatory bowel
disease [47], Crohn’s disease [48], ulcerative colitis [35],
inflamed intestinal mucosa [49] as well as CRC [50-53].
It has been shown that the NFB transcriptional activity
in gastric mucosa is induced during aging [53], that
positive NFB expression as assessed through immuno-
histochemistry is observed in 73.5% of human CRC
tumors independent of age [50], and that levels of
NFB, IKKa and COX2 in tumor epithelial cells from
CRC patients are significantly higher than adjacent nor-
mal tissue [52].
Also relevant to NFB activation and intestinal inflam-
mation is the reported differential regulation of Toll-like
receptors (TLRs) by fatty acids with differing saturation
states [54-56]. TLRs are single membrane-spanning pro-
teins involved in the recognition of microbial-derived
molecules harbouring pathogen-associated molecular
patterns (PAMPs) and activation of various immune cell
responses [57]. Upon activation, TLRs activate NFB
though a complex signalling network culminating with
the activation of IKKa, followed by ubiquitination and
subsequent degradation of IBa and translocation of the
P65 Rel A domain to the nucleus where it binds to and
activates the expression of numerous pro-inflammatory
genes [44]. Specifically, TLR4 has been shown to confer
responsiveness to a number of lipids including lipid A,
the primary biologically active component of LPS, and
that in contrast to saturated fatty acids similar to those
found in lipid A, unsaturated fatty acids inhibit NFB
activity through inhibition of TLR4 or other TLR-asso-
ciated molecules [55,56]. Therefore, it is possible that
the anti-inflammatory effects associated with GTAs are
being exerted through inhibition of TLRs upstream of
NFB. Further work to investigate this hypothesis is
warranted.
NFB, aging and gut microbiota
A final point concerning NFB and GTA metabolism is
that both have age-related implications. We previously
showed that in the general population, there is an
inverse association between the circulating levels of
GTA-446 and age, and that the rate of decline corre-
lated precisely with the increase in CRC incidence with
age [18]. As for NFB, there is substantial literature
regarding its various age-related facets [53,58-63]. For
example, it has been shown that NFB protein levels, as
well as several NFB-targeted pro-inflammatory cyto-
kines, are elevated in endothelial cells of old versus
young subjects, which were also accompanied by
decreased IBa levels in the older group [60]. Microar-
ray analysis further showed that the NFB cis element is
the motif most strongly associated with aging [64] and
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cally aged mice resulted in the reversion of both tissue
and gene expression characteristics to those of young
mice [59]. These and numerous other reports clearly
associate increased NFB activity with multiple aspects
of aging including immunosenescence, antigenic stress,
innate immunity, tissue atrophy, inflammation, cellular
danger responses, apoptosis, DNA damage, oxidative
stress and caloric restriction (see [62] for review). Left
unchecked, therefore, NFB activation is a probable
driving force for many of these critical aging-related
processes.
Given the selectiveness of GTAs in human blood and
their novel hydroxylated and unsaturated fatty acid
structures, the possibility that human-specific gut micro-
bial processes may be involved in the metabolism of
GTAs from dietary sources cannot be excluded. It is
also well known that the intestinal microbiome compo-
sition changes with age due to a number of contributing
factors including reduced mucosal secretion, decreased
nutritional status, changes in luminal pH and increased
drug and antibiotic use [65-68]. There is also evidence
that the gut microbiota is intricately linked to obesity
and metabolic syndrome, and can perpetuate insulin-
resistance and chronic inflammation [69-71], all of
which have been previously implicated with colon can-
cer [42,72-75]. Lastly, it is intriguing to consider that
the modulation of gut microbial composition through
the consumption of probiotics and/or fermented milk
products has been shown to reduce inflammation and
protect against cancer [76-78]. Therefore, investigating
the possible interaction between various gut micro-
organisms and dietary precursors with respect to GTA
metabolism is highly justified.
In summary, our findings collectively suggest a
mechanism whereby the age-related decline in GTAs in
a subset of the general population results in an impaired
ability to control chronic inflammation, which over time
may lead to oncogenic cellular changes. The measure-
ment of GTAs may therefore represent an opportunity
for the early identification of subjects with elevated
inflammatory status and subsequent risk of CRC.
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